In patients hospitalized with COVID-19, adding convalescent plasma to usual care did not reduce 28-d mortality
- 5 October 2021
- journal article
- editorial
- Published by American College of Physicians in Annals of Internal Medicine
- Vol. 174 (10), JC113
- https://doi.org/10.7326/acpj202110190-113
Abstract
Source Citation RECOVERY Collaborative Group. Convalescent plasma in patients admitted to hospital with COVID-19 (RECOVERY): a randomised controlled, open-label, platform trial. Lancet. 2021;397:20... Clinical Impact Ratings Hospitalists: 6 out of 7 Infectious Disease: 6 out of 7 Critical Care: 5 out of 7 Pulmonology: 6 out of 7This publication has 5 references indexed in Scilit:
- Tocilizumab in patients admitted to hospital with COVID-19 (RECOVERY): a randomised, controlled, open-label, platform trialThe Lancet, 2021
- Association of Convalescent Plasma Treatment With Clinical Outcomes in Patients With COVID-19JAMA, 2021
- Dexamethasone in Hospitalized Patients with Covid-19The New England Journal of Medicine, 2021
- Safety UpdateMayo Clinic Proceedings, 2020
- Convalescent Plasma to Treat COVID-19JAMA, 2020